[Clinical significance and relationship of expression of matrix metalloproteinase-2 mRNA with breast cancer metastasis].
To discuss the clinical significance of matrix metalloproteinase-2 (MMP-2) mRNA and the relationship of MMP-2 mRNA expression with breast cancer metastasis. Detect MMP-2 mRNA expression of 30 breast cancer, metastatic lymphnode and 116 clinical breast cancer samples by flurence-quantitative RT-PCR and analysis the relativity of MMP-2 mRNA expression with clinical, pathology factors. MMP-2 mRNA expression in 30 metastatic lymphnode is lower than in primary breast cancer (t = -3.293, P < 0.05). The mRNA expression of MMP-2 in tumor > 2 cm is lower than in tumor </= 2 cm (t = 1.936, P < 0.05). The MMP-2 mRNA expression in stage II, III is lower than in stage I (t = 2.466, P < 0.05). The mRNA expression of MMP-2 in more than 4 lymphnodes positive is lower than in lymphnode 1 - 3 positive (t = 3.202, P < 0.05). The MMP-2 mRNA expression is irrelated with tissue grade, pathologic type, ER, PR and Her-2. MMP-2 mRNA expression is up-regulated in early clinic stage, lymphnode metastatic early stage, and down regulated with tumor progressing. MMP-2 mRNA expression is related with the metastasis of breast cancer.